Nonfatal maltreatment of infants--United States, October 2005-September 2006

    Insights

    In 2006, over 91,000 infants experienced nonfatal maltreatment in the US. Nearly 30,000 were newborns, with neglect being the most common form, highlighting a critical need for further research.

    Area of Science:

    • Pediatrics
    • Public Health
    • Child Welfare

    Background:

    • Child maltreatment is a significant public health concern affecting hundreds of thousands of children annually.
    • Infant fatalities due to maltreatment are disproportionately high, especially in the first week of life.
    • National data on nonfatal infant maltreatment has been limited, hindering targeted prevention efforts.

    Purpose of the Study:

    • To determine the national prevalence and characteristics of nonfatal maltreatment among infants in the United States.
    • To examine the specific risks faced by infants within the first week of life.
    • To inform the development of effective prevention strategies for infant maltreatment.

    Main Methods:

    • Analysis of data from the National Child Abuse and Neglect Data System (NCANDS) for federal fiscal year 2006.
    • Inclusion of data from state and local child protective services (CPS) agencies.
    • Focus on infants aged less than one year, with a specific look at those aged one week or younger.

    Main Results:

    • In fiscal year 2006, 91,278 infants (<1 year) experienced nonfatal maltreatment (23.2 per 1,000 population).
    • A significant portion, 29,881 infants (32.7%), were aged one week or younger at the time of maltreatment.
    • Neglect accounted for 68.5% of maltreatment cases among infants aged one week or younger, though the specific nature of neglect was not detailed.

    Conclusions:

    • Nonfatal maltreatment is a substantial issue for US infants, particularly newborns.
    • The high rate of neglect among the youngest infants necessitates further investigation into its specific forms.
    • More detailed data on infant neglect is crucial for developing targeted and effective prevention interventions.

    Related Concept Videos

    Teratogenicity01:07

    Teratogenicity

    The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    Pharmaceutical Poisoning: Potential Scenarios01:26

    Pharmaceutical Poisoning: Potential Scenarios

    Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...